ウルソデオキシコール酸は,一次性胆道硬化症の効果的な治療法ですか?
Lancet (London, England)
|April 11, 1987
まとめ
ウルソデオキシコール酸 (UDCA) 治療により,肝機能が改善され,一次性胆硬変 (PBC) 患者におけるが軽減されました. 長期にわたるUDCA治療は安全で効果的であり,さらなる制御試験を正当化する.
科学分野:
- 肝臓病理学 肝臓病理学
- 胃腸内科 胃腸内科
- 臨床薬理学 臨床薬理学とは
背景:
- 主要胆管硬化症 (PBC) は,胆管の漸進的な破壊によって特徴づけられる慢性肝疾患です.
- PBCの現在の治療には限界があり,新しい治療薬の探求が必要である.
- ウルソデオキシコール酸 (UDCA) は,潜在的肝臓保護性を持つ天然に存在する胆酸です.
研究 の 目的:
- 主要胆硬化症 (PBC) の患者における長期間のウルソデオキシコール酸 (UDCA) 治療の有効性と安全性を前向きに評価する.
主な方法:
- 毎日UDCA (13-15 mg/kg体重) を摂取しているPBC患者15人を対象とした前向きな研究.
- 血清UDCA濃度,全胆酸濃度,の重度,標準的な肝機能検査を2年間にわたってモニタリングした.
- 肝機能は,UDCAの3ヶ月の中断とUDCAの再導入後に3人の患者で再評価されました.
主要な成果:
- 血清のUDCA濃度は著しく上昇したが,総胆酸は変化しなかった.
- コレスティラミンを必要とするは著しく減少し,標準的な肝機能検査は顕著な改善を示した.
- UDCAの中止は,肝機能検査の悪化につながり,薬の再導入で改善しました.
結論:
- ウルソデオキシコレック酸 (UDCA) の長期治療は,一次性胆管硬化症 (PBC) の管理のための安全で効果的な選択肢であるようです.
- UDCAは,肝機能検査を改善し,PBC患者におけるを和らげるのに有意義な利点を示しています.
- これらの発見を確認するために,ランダム化,制御,ダブルブラインド試験によるさらなる調査が推奨されます.
関連する概念動画
Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:

